Oricell Therapeutics has advanced its GPC3-targeted autologous CAR T therapy, Ori-C101, into a confirmatory registration-directed Phase 2 trial for patients with GPC3-positive advanced hepatocellular carcinoma. The company positions Ori-C101 as the first CAR T program for liver cancer to reach this stage, targeting a challenging solid-tumor immune cell niche. The move comes as CAR T developers seek clearer translational pathways from early efficacy to registration-grade confirmation in solid tumors. Oricell’s selection of a confirmatory Phase 2 framework suggests an endpoint strategy aimed at supporting a regulatory package. If Ori-C101 sustains response rates and durability in this pivotal-like setting, it could reshape how GPC3 is approached in cell therapy manufacturing and trial design for hepatocellular carcinoma.